Search
Recursion Pharmaceuticals Inc
RXRXAdd to Watchlist
3.050USD
-0.100-3.17%
Close 05/13, 16:00（ET）Quotes delayed by 15 min
1.67BMarket Cap
LossP/E TTM
More Details of Recursion Pharmaceuticals Inc Company
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Recursion Pharmaceuticals Inc Info
Ticker SymbolRXRX
Company nameRecursion Pharmaceuticals Inc
IPO dateApr 16, 2021
CEOKhan (Najat)
Number of employees840
Security typeOrdinary Share
Fiscal year-endApr 16
Address41S Rio Grande Street
CitySALT LAKE CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code84101
Phone13852690203
Websitehttps://www.recursion.com/
Ticker SymbolRXRX
IPO dateApr 16, 2021
CEOKhan (Najat)
Company Executives of Recursion Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.22M
+0.74%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
322.07K
-62.58%
Dr. Najat Khan, Ph.D.
Dr. Najat Khan, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
239.01K
-556.08%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
147.23K
+3.33%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Lead Independent Vice Chairman of the Board
Lead Independent Vice Chairman of the Board
73.73K
-24.38%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
23.19K
-105.08%
Mr. Zachary Bogue, J.D.
Mr. Zachary Bogue, J.D.
Independent Director
Independent Director
9.38K
--
Dr. Christopher Gibson, Ph.D.
Dr. Christopher Gibson, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Blake Borgeson, Ph.D.
Dr. Blake Borgeson, Ph.D.
Independent Director
Independent Director
--
--
Dr. Franziska Michor, Ph.D.
Dr. Franziska Michor, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.22M
+0.74%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
322.07K
-62.58%
Dr. Najat Khan, Ph.D.
Dr. Najat Khan, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
239.01K
-556.08%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
147.23K
+3.33%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Lead Independent Vice Chairman of the Board
Lead Independent Vice Chairman of the Board
73.73K
-24.38%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
23.19K
-105.08%
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
39.34M
52.68%
United Kingdom
35.34M
47.32%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
7.66%
BlackRock Institutional Trust Company, N.A.
6.06%
State Street Investment Management (US)
5.43%
Baillie Gifford & Co.
4.51%
Vanguard Portfolio Management, LLC
4.34%
Other
71.99%
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
7.66%
BlackRock Institutional Trust Company, N.A.
6.06%
State Street Investment Management (US)
5.43%
Baillie Gifford & Co.
4.51%
Vanguard Portfolio Management, LLC
4.34%
Other
71.99%
Shareholder Types
Shareholders
Proportion
Investment Advisor
40.50%
Investment Advisor/Hedge Fund
12.87%
Venture Capital
4.66%
Hedge Fund
3.10%
Individual Investor
2.28%
Research Firm
2.04%
Bank and Trust
1.25%
Sovereign Wealth Fund
1.09%
Pension Fund
0.25%
Other
31.94%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
721
388.34M
74.06%
+46.55M
2025Q4
685
320.96M
62.42%
-4.35M
2025Q3
669
303.20M
58.89%
-18.41M
2025Q2
658
317.16M
74.44%
-11.74M
2025Q1
665
322.62M
81.56%
-7.38M
2024Q4
611
317.29M
80.77%
+25.35M
2024Q3
560
281.65M
104.01%
-6.72M
2024Q2
527
272.94M
105.41%
+14.66M
2024Q1
478
234.97M
104.72%
-10.28M
2023Q4
433
227.80M
110.74%
+18.50M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
ARK Investment Management LLC
37.32M
7.15%
+3.77M
+11.24%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
31.81M
6.09%
+4.58M
+16.83%
Dec 31, 2025
State Street Investment Management (US)
25.33M
4.85%
+7.06M
+38.67%
Dec 31, 2025
Baillie Gifford & Co.
23.77M
4.55%
-203.72K
-0.85%
Dec 31, 2025
SB Global Advisers Ltd
13.64M
2.61%
-1.03M
-7.03%
Dec 31, 2025
Kinnevik AB
13.43M
2.57%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
10.93M
2.09%
+1.31M
+13.62%
Dec 31, 2025
DCVC Management Co, LLC
5.94M
1.14%
--
--
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ARK Genomic Revolution ETF
5.69%
First Trust Nasdaq AI and Robotics ETF
1.75%
Global X HealthTech ETF
1.73%
AXS Green Alpha ETF
1.36%
ARK Innovation ETF
1.17%
State Street SPDR S&P Biotech ETF
0.95%
Virtus LifeSci Biotech Clinical Trials ETF
0.72%
WisdomTree BioRevolution Fund
0.65%
Direxion Daily S&P Biotech Bull 3X Shares
0.62%
Franklin Genomic Advancements ETF
0.44%
View more
ARK Genomic Revolution ETF
Proportion5.69%
First Trust Nasdaq AI and Robotics ETF
Proportion1.75%
Global X HealthTech ETF
Proportion1.73%
AXS Green Alpha ETF
Proportion1.36%
ARK Innovation ETF
Proportion1.17%
State Street SPDR S&P Biotech ETF
Proportion0.95%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.72%
WisdomTree BioRevolution Fund
Proportion0.65%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.62%
Franklin Genomic Advancements ETF
Proportion0.44%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
